Drug Combination Details
| General Information of the Combination (ID: C27185) | |||||
|---|---|---|---|---|---|
| Name | Silibinin NP Info | + | Cisplatin Drug Info | ||
| Structure |
|
+ |
|
||
| Disease |
Prostate cancer
[ICD-11: 2C82]
|
Investigative | [1] | ||
|
Ovarian cancer
[ICD-11: 2C73]
|
Investigative | [2] | |||
|
Testicular carcinoma
[ICD-11: 2C80]
|
Investigative | [3] | |||
| Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally | ||||||
|---|---|---|---|---|---|---|
| α. Enhancing Drug Efficacy by This Combination | ||||||
| Augmenting Drug Sensitivity | Click to Show/Hide | |||||
| Experiment 1 Reporting the Effect of This Combination | [1] | |||||
| Molecule(s)
Regulation |
Up-regulation | Cleavage | CASP3 | Molecule Info |
Pathway MAP
|
|
| Down-regulation | Expression | CCNB1 | Molecule Info |
Pathway MAP
|
||
| Up-regulation | Expression | CHK1 | Molecule Info |
Pathway MAP
|
||
| Down-regulation | Expression | MPIP3 | Molecule Info |
Pathway MAP
|
||
| Up-regulation | Cleavage | PARP1 | Molecule Info |
Pathway MAP
|
||
| Down-regulation | Expression | POLD1 | Molecule Info |
Pathway MAP
|
||
| Up-regulation | Expression | WEE1 | Molecule Info |
Pathway MAP
|
||
| Biological
Regulation |
Induction | Cell cycle arrest in G2/M phase | ||||
| Up-regulation | Cytochrome c release | |||||
| In-vitro Model | DU145 | CVCL_0105 | Prostate carcinoma | Homo sapiens | ||
| Experimental
Result(s) |
Silibinin sensitizes human prostate carcinoma DU145 cells to cisplatin-induced growth inhibition and apoptotic death. | |||||
| β. Decreasing Adverse Drug Reaction by This Combination | ||||||
| Decreasing Adverse Drug Reaction | Click to Show/Hide | |||||
| Experiment 1 Reporting the Effect of This Combination | [2] | |||||
| In-vitro Model | L-02 | CVCL_6926 | Ovarian cancer | Homo sapiens | ||
| A2780 | CVCL_0134 | Ovarian endometrioid adenocarcinoma | Homo sapiens | |||
| Experimental
Result(s) |
silibinin could restore the sensitivity of cisplatin in drug-resistant human ovarian cancer cells and reduce durg-induced hepatotoxicity in cell level. | |||||
